The RB/p105 and p107 genes of the retinoblastoma family are tumor suppressor genes whose proteins are inactivated by interaction with T-antigen proteins encoded by polyomaviruses (e.g., simian virus 40 and human JC virus), which have been found to be highly tumorigenic in animals. A variety of indirect evidence suggests that another member of the retinoblastoma gene family, RB2/p130, is also a tumor suppressor gene. To investigate the putative tumor suppressor activity of RB2/p130 more directly, we utilized a tetracycline-regulated gene expression system to control expression of the encoded protein pRb2/p130 in JC virusinduced hamster brain tumor cells and to study the effects of pRb2/p130 on the growth of such tumor cells in nude mice. The ability of pRb2/p130 to interact with JC virus T antigen was also studied. Methods: Northern blot hybridization analyses were performed on samples of total cellular RNA to measure RB2/p130 and ␤-actin messenger RNA levels. Immunoprecipitation and western blot analyses were used to determine T-antigen and pRb2/p130 protein levels and to assess the phosphorylation status of these proteins. Tumor cells were injected subcutaneously into nude mice, and tumor growth, with or without induced expression of pRb2/ p130, was monitored. Results: Induction of pRb2/p130 expression brought about a 3.2-fold, or 69% (95% confidence interval = 64%-73%), reduction in final tumor mass in nude mice. We also demonstrated that JC virus T antigen binds hypophosphorylated pRb2/p130 and that stimulation of pRb2/p130 expression overcomes cellular transformation mediated by this antigen. Conclusion: Our findings support the hypothesis that RB2/p130 is a tumor suppressor gene. [J Natl Cancer Inst 1998;90:1451-60]
JC virus (JCV) is the etiologic agent of progressive multifocal leukoencephalopathy (PML), a demyelinating disease of the central nervous system generally seen in immunocompromised patients, through its infection and lytic destruction of myelinproducing oligodendroglial cells (1) . Patients with PML also exhibit bizarre astrocytes with tumor-like glial changes due to their selective targeting by JCV (2) . JCV is a member of a family of polyomaviruses that includes BK virus (BKV) and simian virus 40 (SV40). These polyomaviruses have been shown to be highly tumorigenic in animals. In hamsters, intracerebral injection of BKV results in choroid plexus papillomas and ependymomas (cancer of the membrane lining of the ventricles of the brain and of the central canal of the spinal cord), and SV40 produces ependymomas, whereas JCV leads to the induction of cerebellar medulloblastomas, glioblastomas, malignant astrocytomas, and primitive neuroectodermal tumors. The deregulatory effects of each on normal cell growth control and the transforming and oncogenic properties of polyomaviruses stem from expressing viral T-antigen (TAg) proteins encoded in the early region of the viral genomes (3) . JCV TAg is 72% homologous at the amino acid level and shares many functional attributes with its well-characterized SV40 counterpart (1, 4) . The transforming capacity of SV40 TAg is thought to arise from its ability to interact with and thereby inactivate several tumor-suppressive proteins and/or growth-suppressive proteins such as those of the retinoblastoma (Rb) family (pRb/p105, p107, and pRb2/p130) and the ''guardian of the genome'' p53 (3, 5) . Recent evidence (5-7) supports the application of such a model to explain the tumorigenic potential of SV40 in some human mesotheliomas. JCV TAg, like SV40 TAg, binds pRb, p107, and p53 but with a lower affinity of interaction (8) (9) (10) (11) . Transcriptional regulation of the JCV promoter mandates the central nervous system tropism of tumors induced by JCV (12) . Failure of viral DNA replication through the absence of an intact viral genome or through species-specific restrictions of JCV polymerase to primates enhances the oncogenic potential of JCV TAg, leading to cellular transformation and the formation of neuroectodermal tumors instead of PML. This hypothesis is supported by the highly oncogenic potential of JCV in rodents and by the demonstration of JCV DNA, harboring a viral mutation that halts virion formation yet allows RNA and TAg protein expression, in the brain of an immunocompetent patient with oligoastrocytoma (13) .
The fact that many DNA tumor viruses, such as JCV, SV40, adenovirus, and human papillomavirus, elicit their transforming functions by binding and functionally inactivating proteins of the Rb family testifies to the importance of the Rb family in maintaining normal cell growth control (1, 3, 5) . Proteins of the Rb family are highly homologous in the ''pocket'' region, which is targeted by the viral oncoproteins and is responsible for many functional interactions (14) (15) (16) (17) (18) (19) . Functionally, all the Rb family members show cell type-specific growth-suppressive properties unique to each member. They each bind and temporally modulate in a distinct manner the activity of specific members of the E2F family of transcription factors and are phosphorylated in a cell cycle-dependent mode (3, 20) . These activities and interactions allow the Rb family to serve as signal transducers linking the cell cycle and transcriptional machinery. Increasing evidence is mounting that, even though the Rb family members may be able to complement each other, they are not fully functionally redundant. This situation was first demonstrated in the T98G human glioblastoma cell line, which is refractory to the effects of pRb and p107 but is growth suppressed by pRb2/p130 overexpression (21) .
The prototypic tumor suppressor gene RB is mutated in a number of human tumors (20) . The fact that transforming oncoproteins such as SV40 TAg must maintain an intact Rb family-binding domain (LXCXE domain) to transform RB null cells indicates that p107 and pRb2/p130 are also strategically important targets for SV40 TAg-mediated transformation and implicates them as putative tumor suppressor genes (22) . In support of an involvement of the RB2/p130 gene in human cancer, this gene maps to the human chromosomal locus 16q12.2, a region in which deletions have been found in several human neoplasias, including breast, ovarian, hepatic, and prostatic cancers (23) . Immunohistochemical data examining the expression of the Rb family proteins in 237 patient samples of lung carcinoma and 100 patient samples of endometrial carcinoma suggest an independent role for the reduction or loss of pRb2/p130 expression in the formation and/or progression of lung and endometrial carcinomas (24) (25) (26) . In addition, we and others have detected mutations in the RB2/p130 gene in human cell lines of small-cell lung carcinoma (27) and adenocarcinoma of the lung as well as in tumor specimens from patients (Cinti C, Claudio PP, Giordano A: unpublished data). This observation suggests that functional inactivation of one or more of the Rb family genes by genomic mutation or by transforming oncoprotein may provide the cell with a growth advantage resulting in tumor formation.
These data, in combination with data obtained from in vitro assays demonstrating the growth-inhibitory effects of pRb2/ p130 expression, led us to examine the possible antitumorigenic effects of pRb2/p130 expression in vivo (21, 28) . To accomplish this goal, we exploited the JCV model system, where the endogenous Rb family members as well as p53 are inactivated by JCV TAg. We took advantage of a tetracycline-regulated expression system to create an inducible system for the expression of the pRb2/p130 protein in the HJC-15c clonal cell line originating from a JCV-induced hamster brain tumor (29) and analyzed the effects of pRb2/p130 expression on tumor formation in vivo.
MATERIALS AND METHODS

Plasmids
The eukaryotic expression plasmid pcDNA3 conferring neomycin resistance was purchased from Invitrogen Corp., Carlsbad, CA. The plasmid pTet-tTak containing the gene for the tetracycline transactivator (tTA) under the control of the tetracycline promoter (Tetp) was purchased from Life Technologies, Inc. (GIBCO BRL), Gaithersburg, MD. The full-length complementary DNA (cDNA) of the human RB2/p130 gene was subcloned downstream of the Tetp into the HindIII restriction site of the UHD hyg BH plasmid, which also confers the hygromycin resistance gene as previously described (30) . The clone was confirmed by both restriction and sequence analyses.
Transfections and Cell Culture
Primary embryonal human kidney 293 cells (transformed by sheared human adenovirus type 5) and African green monkey kidney COS-7 cells (transformed by SV40) were purchased from the American Type Culture Collection, Manassas, VA. The HJC-15c clonal cell line [originating from a JCV-induced hamster brain tumor, initially described in 1995 (29) ], HJC⌬5 cells, 293 cells, and COS-7 cells were grown in Dulbecco's modified Eagle medium (DMEM) supplemented with 5% fetal calf serum (Sigma Chemical Co., St. Louis, MO) and the antibiotics streptomycin (10 g/mL) and penicillin (100 U/mL). Both HJC⌬5 and HJC12 cells were maintained in DMEM supplemented with 5% fetal calf serum (Life Technologies, Inc.) and the antibiotics streptomycin (10 g/mL), penicillin (100 U/mL), and tetracycline (2 g/mL) (Sigma Chemical Co.).
All transfections were performed by use of the standard suspension calcium phosphate precipitation method (21, 28) . The HJC⌬5 cell line was formed by stable cotransfection of the HJC-15c cell line with pcDNA3 (to provide the neomycin selection marker) and pTet-tTak at a 1 : 50 ratio, respectively. The cells were grown under selective conditions in the presence of the neomycin analogue G418 (Life Technologies, Inc.) at a concentration of 1000 g/mL. Individual colonies were picked and transiently transfected with the UHD hyg BH-RB2/p130 plasmid in the presence and the absence of 2 g/mL tetracycline in the medium and screened for induction of pRb2/p130 expression. Forty-eight hours after transfection, the cells were harvested and screened by western blot analysis with the ADL1 polyclonal antibody to pRb2/p130 (produced in our laboratory) to select for the clone with the best induction of pRb2/p130 expression when grown in the absence of tetracycline. The positive clones were then grown in the absence of tetracycline for a prolonged period (4-5 weeks) to ensure that the expression of the tTA was not affecting cell growth or morphology, since extremely high levels of tTA may be toxic. The HJC12 clone was formed by stable transfection of the HJC⌬5 clone with the UHD hyg BH-RB2/ p130 plasmid, and the cells were maintained with 500 g/mL G418 and selected with 500 g/mL hygromycin (Boehringer Mannheim Biochemicals, Indianapolis, IN) as well as 2 g/mL tetracycline to repress exogenous pRb2/p130 expression. The clones were grown in the constant presence of 2 g/mL tetracycline. The clones were screened by placement of the cells in medium with or without tetracycline for 48 hours and western blotting with the ADL1 antibody for the clone with the best induction of pRb2/p130 expression in the absence of tetracycline.
RNA Extraction and Northern Blot Analysis
Cytoplasmic RNA was extracted with the use of the RNAzol B method (CINNA/BIOTECX, Friendswood, TX) from the HJC12 and HJC⌬5 cell lines grown in the presence or absence of 2 g/mL tetracycline. RNAs were quantitated spectrophotometrically, and their integrity was confirmed by fractionation of 1 g of RNA on a 1% agarose gel with ethidium bromide staining. Then 40 g of RNA of each sample was subjected to electrophoresis through a 1% denaturing agarose gel containing formaldehyde. RNAs were transferred overnight onto an Immobilon N nylon membrane (Millipore Corp., Bedford, MA) with 20× standard saline citrate (SSC), and RNA was UV cross-linked onto the membrane. The membrane was prehybridized at 42°C in a solution containing the following: 5× sodium chloride, sodium phosphate, and EDTA (SSPE), 10× Denhardt's solution, 100 g/mL fresh denatured, sheared salmon sperm DNA, 50% formamide, and 2% sodium dodecyl sulfate (SDS) for 12 hours; it was then hybridized with ␣-[ 32 P]deoxycytidine triphosphate (dCTP) (DuPont NEN, Boston, MA) random primer-labeled (Boehringer Mannheim Biochemicals) cDNA probes with the use of 3 × 10 6 cpm/mL. The probe of 1032 base pairs (bp) representing the 5Ј region of the RB2/p130 gene was purified by the gene clean method (Bio 101, Inc., Vista, CA). Filters were also probed with ␤-actin to normalize the signal detected. After overnight hybridization, blots were washed twice in 2× SSC and 0.2% SDS at room temperature for 10 minutes and three times in 0.1× SSC and 0.1% SDS at 42°C for 20 minutes and then exposed for 12 hours to Kodak x-ray film at −80°C with the aid of an intensifying screen. Stringent conditions were used for the northern blots to distinguish the exogenous human RB2/p130 messenger RNA (mRNA) expression from that of the endogenous hamster.
Western Blotting, Immunoprecipitation, and Cell Labeling
Western blot analysis and immunoprecipitations were performed as previously described (28) . Protein concentration was assayed by Bradford analysis (BioRad Laboratories, Inc., Hercules, CA) and was confirmed by running 5 g of protein on a 10% SDS-polyacrylamide gel and by staining with Coomassie blue. Primary rabbit polyclonal anti-pRb2/p130 COOH antibody (ADL1, produced in our laboratory) was used at a dilution of 1 : 1000 in a solution of TBT-T (Trisbuffered saline plus 0.5% Tween-20), 5% dry milk for western blot analysis, and 5 L for each 100 g of protein for immunoprecipitation. The loading and transfer of equal amounts of protein were confirmed by staining the membranes with Red Ponceau (Sigma Chemical Co.). The specificity of the ADL1 antibody for recognizing pRb2/p130 in western blot analysis and immunoprecipitation was previously demonstrated (28, 31) . The PAB 416 monoclonal antibody that cross-reacts with JCV and SV40 TAg (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY) was used at a dilution of 1 : 10 for western blot analysis and 100 L for each 100 g of protein for immunoprecipitation. The immunoaffinity-purified monoclonal Ab-1 antibody (Oncogene Science, Inc., Cambridge, MA) that specifically recognizes SV40 TAg was used at a dilution of 1 : 500 for western blot analysis. Proteins were radioactively labeled by incubating 10-cmdiameter culture plates at 75% cell confluence with 2.0 mCi of 32 PO 4 (DuPont NEN) in 4 mL of phosphate-free medium for 4 hours (32).
Flow Cytometry Analysis
HJC⌬5 and HJC12 cells were washed with phosphate-buffered saline (PBS), plated at 2.5 × 10 6 cells per plate in the presence or absence of tetracycline, and then harvested at 24 hours. Fluorescence-activated cell sorting (FACS) analysis was performed three separate times in triplicate on a Coulter Elite apparatus (Beckman Coulter, Inc., Fullerton, CA) to determine the cell cycle distribution of the cells as previously described (28) .
Colony Formation Assay
The colony formation assays were performed three separate times in triplicate as described previously (21, 28) . HJC12 cells were plated at a density of 1.5 × 10 5 cells per plate in the presence or absence of 2 g/mL tetracycline. The expression of pRb2/p130 was induced in HJC12 cells by washing the cells thoroughly with PBS and placing them in fresh medium lacking tetracycline. Expression of exogenous RB2/p130 was repressed by the addition of 2 g/mL tetracycline to the medium. Selective pressure was continued by maintaining the cells in 500 g/mL G418 and 250 g/mL hygromycin.
Animal Studies
Animal care and humane use and treatment of mice were in strict compliance with 1) institutional guidelines, 2) the Guide for the Care and Use of Laboratory Animals (National Academy of Sciences, Washington, DC, 1996), and 3) the Association for Assessment and Accreditation of Laboratory Animal Care International (Rockville, MD, 1997). Tumors were generated subcutaneously in nude mice (female NU/NU-nuBR outbred, isolator-maintained mice, 4-5 weeks old, from Charles Rivers Laboratories, Wilmington, MA) by the injection of HJC12 or HJC⌬5 cells. Before injection, cells were grown in medium containing 2 g/mL tetracycline and washed with PBS. The mice were treated with tetracycline for 4 days before injection. While under anesthesia with isopropane gas, the mice were given subcutaneous injections along their left and right flanks at two sites per mouse with 5 × 10 6 cells per flank. There were four groups of animals and three animals per group. Two groups were given injections of HJC12 cells, and treatment with tetracycline continued following injection in one group [HJC(12+)], whereas another group [HJC(12−)] ceased to be administered tetracycline after injection of the cells. The two control groups were given injections of HJC⌬5 cells, and one group [HJC⌬(5+)] continued to receive tetracycline while the other control group [HJC⌬(5−)] did not. The animals were weighed once per week. To follow tumor growth, we measured with a caliper the longest axis of the tumor and the axis perpendicular to this. We calculated tumor volume by using the following formula: tumor volume ‫ס‬ (length)(width) 2 ÷ 2. We administered tetracycline to the animals by adding 4.525 g of tetracycline hydrochloride soluble powder (T-SOL 10, containing 10 g of tetracycline HCl activity per 181 g) along with 2.5 g of sucrose to autoclaved amber drinking bottles containing 250 mL H 2 O to make a solution of 1 mg/mL active tetracycline hydrochloride and 1% sucrose that was prepared fresh and changed daily. Animals were killed by CO 2 asphyxiation 10 weeks after injection of the cell lines or when the tumors reached a size of approximately 1 cm 3 . The tumors were then excised and weighed before they were processed. One mouse in the HJC12(+) group died prematurely while under anesthesia 3 weeks into the first study and was dropped from the final data analysis of the tumor weights. Tissues to be used for molecular biologic analysis were snap-frozen in liquid nitrogen and stored at −80°C. Tissues to be sectioned were placed in OCT (Sakura Finetek USA, Inc., Torrance, CA), frozen in liquid nitrogen, and stored at −80°C or preserved in neutral buffered formalin at 4°C prior to embedding in paraffin. This process was repeated in the second study with the use of the same conditions except that the control group (HJC⌬5 plus or minus tetracycline) numbers were changed to two mice per group and the experimental group (HJC12 plus or minus tetracycline) numbers were increased to four mice per group. A third study was conducted with the use of essentially the same conditions, except that tetracycline was administered through the subcutaneous implantation of 60-day time-release pellets (42 mg in total) designed to deliver 0.7 mg of tetracycline (+) or placebo (−) per day (Innovative Research of America, Sarasota, FL). HJC12(+) and HJC12(−) groups consisted of six and eight mice, respectively, and the HJC⌬5(+) and HJC⌬5(−) groups contained two mice each.
Immunohistochemistry and Cytochemistry
Immunohistochemistry and cytochemistry were performed with use of our ADL1 (rabbit polyclonal ␣-pRb2/p130 COOH) immune serum at a dilution of 1 : 1000 in PBS or the PAB 416 monoclonal antibody against JCV and SV40 TAg at a dilution of 1 : 500 in PBS with the use of the Vectastain ABC kit (rabbit immunoglobulin G [IgG] and mouse IgG, respectively; Vector Laboratories, Inc., Burlingame, CA), essentially as described previously (6, 24, 25) .
Statistical Analysis
For the flow cytometry analyses, the mean increase in the G 0 /G 1 population following induction of pRb2/p130 expression in three separate experiments and the standard deviation of the data range were calculated and used to determine the confidence interval (CI) at a significance of .05 (alpha ‫ס‬ .05). All analyses of tumor weight and volume were done after first transforming to log 10 scale. The reported average weights are thus geometric means. For weights, we used the t distribution for CIs for weights. The calculation was done for the logarithm of the total tumor weight per mouse and then transformed back to the original scale and divided by 2 to express the results as the mean weight per tumor. For the CIs for the ratios of weights, the intervals were first calculated for the difference of log weights and then transformed back. The overall P value for comparing the size difference between tumors generated in the mice given tetracycline and those not given tetracycline was based on a two-sided Wilcoxon test of total tumor weight per mouse with the use of the exact method for small sample sizes and with stratification by experiment. Volumes were compared by an analysis of variance of log volumes, excluding values where the tumor was palpable but not measurable. The analysis allowed for differences between mice and for the correlation due to repeated measurements (multiple days) on each tumor. Although not reported in the ''Results'' section, we examined whether the group effect-the administration (+) or no administration (−) of tetracycline-was consistent over the time period that the tumor volume was measured. In all three cases, there was no large or statistically significant inconsistency (Pജ.21).
RESULTS
We used a modified tetracycline-regulated method to create an autoregulatory inducible RB2/p130 gene expression system in the HJC-15c cell line, one of five clonal cell lines originating from a human polyomavirus-induced hamster brain tumor (33) . We chose the HJC-15c clonal cell line because it exhibited the lowest expression of RB2/p130 mRNA (data not shown) and the shortest doubling time of the five clones (HJC-15a, HJC-15b, HJC-15c, HJC-15d, and HJC-15e) (29) . We used the parental cell line HJC-15c to create the control cell line HJC⌬5, which contains the tTA under the control of the Tetp. We used HJC⌬5 cells to form the HJC12 cell line, which contains, in addition to tTA, the full-length cDNA of the human RB2/p130 gene downstream of the Tetp (see ''Materials and Methods'' section for details). In this system, expression of RB2/p130 is repressed in the presence of the antibiotic tetracycline and induced in its absence. As seen in Fig. 1 , the expression of RB2/p130 was enhanced at the mRNA level (Fig. 1, A) , and it was enhanced 160-fold at the protein level (Fig. 1, B) upon withdrawal of tetracycline from the medium. Equal loading of the protein gel and equivalent protein transfer were confirmed by staining the membrane with Red Ponceau (data not shown).
Next, the effects of induction of pRb2/p130 on the growth of JCV Tag-transformed cells were examined. Equal numbers of HJC12 cells were plated in medium containing or lacking tetracycline and were grown for 15 days. Induction of pRb2/p130 resulted in a dramatic growth arrest of the cells as evidenced by colony formation assay (Fig. 2, A) . HJC12 and HJC⌬5 cells were each plated in the presence or absence of tetracycline for 24 hours and then harvested. Their cell cycle profile was examined by flow cytometry analysis. As shown in Fig. 2 , A, upon the induction of pRb2/p130 expression, nearly 90% of the cells were found in the G 0 /G 1 stage, corresponding to a mean increase of 41.6% (95% CI ‫ס‬ 40.1%-43.1%) in the G 0 /G 1 population in three separate experiments (Fig. 2, B) . These results are in agreement with the data of transient transfection experiments using the parental cell line HJC-15c (data not shown) and other human cell lines (28) that also found that the growth-suppressive action of pRb2/p130 is specific to the G 0 /G 1 phase of the cell cycle. This effect was specific for pRb2/p130 expression, since withdrawal of tetracycline from the HJC⌬5 parental cells did not affect their cell cycle distribution (Fig. 2, B) .
We next wanted to determine if JCV TAg, like its SV40 counterpart, was interacting with pRb2/p130. Prior to this determination, we had confirmed that cell lines HJC⌬5 and HJC12 were indeed transformed by JCV and were not crosscontaminated with SV40 TAg. Western blot analysis with the PAB 416 monoclonal antibody that cross-reacts with JCV and SV40 TAg detected a band of 90 kilodaltons (kd) in the HJC cell lines and COS-7 cells that are transformed with SV40 TAg but not in 293 cells as a negative control. Reprobing the blot with the Ab-1 antibody that specifically recognizes SV40 TAg detected the 90-kd band of TAg only in COS-7 cells, thus confirming that the HJC cell lines contain only JCV and not SV40 TAg (data not shown). Immunoprecipitation of cell lines HJC⌬5 and HJC12 grown in the presence or absence of tertracycline with antipRb2/p130 immune serum (ADL1) followed by western blot analysis with PAB 416 detected the physical interaction between pRb2/p130 and JCV TAg (Fig. 3, A) . Combined immunoprecipitation/western blot analysis using PAB 416/anti-pRb2/p130, respectively, also detected this complex (data not shown). The association between pRb2/p130 and JCV TAg increased upon the induction of pRb2/p130 expression (HJC12 cells grown in the absence of tetracycline) (Fig. 3, A) . Since the function of pRb2/p130 is thought to be modulated through phosphorylation, we next examined its phosphorylation status in the JCV TAg complex. The proteins in the HJC12 cells grown in the absence or presence of tetracycline were labeled with [
32 P]orthophosphate, immunoprecipitated with normal rabbit serum, anti-pRb2/ p130, or PAB 416, and then run on an 8% SDS-polyacrylamide gel. Anti-pRb2/p130 precipitated pRb2/p130, with only the hyperphosphorylated form being visualized, and the 92-kd phosphorylated form of JVC TAg. PAB 416 immunoprecipitated both the 88-and 92-kd phosphoforms of JVC TAg but failed to precipitate pRb2/p130 (Fig. 3, B) . Therefore, the 92-kd form of JVC TAg associates with hypophosphorylated pRb2/p130 but fails to bind hyperphosphorylated pRb2/p130. This association was detected in the HJC12 cells in both the uninduced and induced states, as well as in the HJC⌬5 cells (data not shown), demonstrating that this association is specific and is not merely due to inordinately high levels of the pRb2/p130 protein and that neither tetracycline nor tTA affects complex formation.
Because of the in vitro data previously mentioned, we examined whether or not induction of pRb2/p130 is able to overcome JVC TAg-mediated cellular transformation and tumor formation in vivo. Nude mice were given injections of 5 × 10 6 of either HJC⌬5 or HJC12 cells in each flank (two flanks per mouse), and the mice were administered a solution of 1 mg/mL active tetracycline hydrochloride plus 1% sucrose (+) or only 1% sucrose alone (−) in their drinking water (see ''Materials and Methods'' section for details). The first study involved three mice in each of the four groups. This experiment was repeated under the same conditions except that the HJC12(+) and HJC12(−) group numbers were increased to include four mice per group and the HJC⌬5(+) and HJC⌬5(−) control group numbers were decreased to two mice per group. The induction of pRb2/p130 expression in the HJC12(−) group greatly retarded tumor growth compared with the tumor growth in the HJC12(+) group, whereas no statistically significant difference was found between mice in the HJC⌬5(−) and the HJC⌬5(+) groups (Fig. 4,  A-F) . Once the tumor volume became measurable, the tumor volume in the mice in the HJC12(+) group was on average 12.90 (95% CI ‫ס‬ 7.48-22.23) times larger than that in the mice in the HJC12(−) group in the first study and 8.72 (95% CI ‫ס‬ 3.34-22.78) times larger than that in the mice in the HJC12(−) group in the second study, which translates to an average reduction in measurable tumor volume by 88.5% and 92.2% from the induction of pRb2/p130 throughout the first and second studies, respectively. These average differences in tumor volume in the mice in the HJC12 group were maintained throughout the period of the studies and were found to be highly statistically significant (P<.001 for study 1; P ‫200.ס‬ for study 2); however, no statistically significant difference in the mean tumor volume over the time of the study was found between the HJC⌬5(+) and HJC⌬5(−) groups of mice (P ‫)83.ס‬ (Fig. 4, E and F) . There was at least some growth of the cells in each of the mice, which demonstrated that the cells injected were viable and that the growth-inhibitory effects were not due to nonviability of the cells before or during the injection process. The combined weights of the excised tumors from each of the mice in the HJC12(+) and HJC12(−) groups as well as from each of the mice in the HJC⌬5(+) and HJC⌬5(−) groups at the conclusion of the two experiments were compared. No statistically significant dif- ferences were found in the tumor weights of mice in the HJC⌬5(+) or HJC⌬5(−) groups in both studies. Tumors in the HJC⌬5 group grew at a faster rate than those in the HJC12 group, and mice in the HJC⌬5 group bearing tumors had to be killed earlier than mice in the HJC12 group bearing tumors, since they outgrew the parameters of the experiment. Mice of the HJC12(+) and HJC12(−) groups were killed simultaneously in each study. In the first study, the mean weight of the tumors in the HJC12(+) group was 0.123 g (95% CI ‫ס‬ 0.042-0.361), and the mean weight of the tumors in the HJC12(−) group was 0.042 g (95% CI ‫ס‬ 0.017-0.104); therefore, the induction of pRb2/ p130 expression retarded tumor growth by 2.9-fold or 66% (95% CI ‫ס‬ 17%-86%). In the second study, the mean weight of the tumors in the HJC12(+) group was 0.079 g (95% CI ‫ס‬ 0.020-0.314), and the mean weight of the tumors in the HJC12(−) group was 0.023 g (95% CI ‫ס‬ 0.014-0.037); therefore, induction of pRb2/p130 in this experiment inhibited tumor growth by 3.4 times or 71% (95% CI ‫ס‬ 11%-81%). If we combined the data of the two experiments, induction of pRb2/p130 expression suppressed tumor growth on average by approximately 3.2-fold or 69% (95% CI ‫ס‬ 64%-73%). This dichotomy in the final tumor weights in the mice of the HJC12(+) and HJC12(−) groups was found to be statistically significant (P ‫.)310.ס‬ The study was also performed a third time under the same conditions except that the method of administering tetracycline was through the subcutaneous implantation of a 42-mg 60-day time-release pellet designed to deliver 0.7 mg of tetracycline (+) or placebo (−) per day. The HJC12(+) and HJC12(−) groups consisted of six and eight mice, respectively, and the HJC⌬5(+) or HJC⌬5(−) control groups contained two mice each. Again, there was no statistically significant difference between the tumor volume over time and the final tumor weight in the mice in the control HJC⌬5(+) or HJC⌬5(−) groups, as noted in the previous experiments. The mean weight of the excised tumors in the mice of the HJC12(+) group was 0.236 g (95% CI ‫ס‬ 0.148-0.375), and the mean weight of the tumors in the mice of the of HJC12(−) group induced to express pRb2/p130 was 0.055 g (95% CI ‫ס‬ 0.012-0.490). Consistent with the first two studies, stimulation of pRb2/p130 expression inhibited tumor growth by approximately 4.3-fold or 77% (95% CI ‫ס‬ 10%-94%). The mean inhibition of tumor growth from the induction of pRb2/p130 expression over the three studies was found to be 72% (95% CI ‫ס‬ 38%-87%), which was highly statistically significant (P<.001).
Suppression of tumor growth was dependent on an increase in pRb2/p130 expression in vivo, as shown by western blot analysis with anti-pRb2/p130 of protein extracts from tumor specimens (Fig. 5) . Equal loading and transfer of the proteins were confirmed by staining the membrane with Red Ponceau (data not shown). The expression of both pRb2/p130 and JCV TAg remained nuclear upon induction of pRb2/p130, as confirmed by cytochemistry (Fig. 6,  A and B) . The HJC12 and HJC⌬5 cells formed tumors in the nude mice with a characteristic histology of glioblastoma multiforme ( Fig. 6, C; data not shown). Induction of pRb2/p130 expression and co-localization within the nuclei of the protein with JCV TAg in vivo were also demonstrated by immunohistochemistry of parallel tumor sections and cytochemistry (Fig. 6 , A-E; data not shown).
DISCUSSION
We report here the development of an inducible system of pRb2/p130 expression that functions in vitro and in vivo. This will be a valuable reagent in the future to further decipher the growth-suppressive pathways of pRb2/p130. Using this system, we have confirmed previous in vitro data that induction of pRb2/ p130 is growth inhibitory, resulting in a G 0 /G 1 growth arrest (21, 28) . A higher fraction of the cells was found in the G 0 /G 1 population with the use of the inducible clone (HJC12) than was found by transient transfection assays. This result is probably due to more uniform expression of the protein in the stable clone upon induction than that achieved by the analysis of a mixed population of cells obtained from the relatively low efficiency of transient cotransfection of pRb2/p130 with a CD20 cell surface selection marker. Alternatively, this result may reflect differences in expression achieved by the cytomegalovirus and Tetp promoters or may be due to cell type-specific effects of the protein. To our knowledge, we have also shown for the first time that pRb2/p130 is targeted by the JCV TAg oncoprotein, which associates only with hypophosphorylated pRb2/p130. Because of the cell cycle-dependent phosphorylation of pRb2/p130, it is hypothesized that pRb2/p130, like p105, is negatively modulated by phosphorylation (28) . Phosphorylation of pRb2/p130 may affect its ability to associate with and regulate the activity of transcription factors such as the E2F family or even possibly its ability to associate with and inhibit the activity of specific cyclin-dependent kinases (20, 34) . Considering this theory, one may hypothesize that JCV TAg targets and sequesters the biologically active form of pRb2/p130, thereby functionally inactivating the growth-regulatory role of the protein. Since the HJC cell lines express such low endogenous levels of pRb2/p130, even lower than those predicted by their mRNA expression, JCV Tag, like SV40 Tag, may be altering the phosphorylation state and targeting pRb2/p130 for degradation (35) . This hypothesis is supported by the conservation of the LXCXE domain and the HPD motif in the amino-terminal region of JCV Tag, both of which are required for SV40 TAg to affect pRb2/p130 stability and phosphorylation (35) . With this in mind, the finding of the specific association of JCV TAg with only the hypophosphorylated form of pRb2/p130 may be a reflection of the ability of JCV TAg to reduce the presence of hyperphosphorylated pRb2/p130, and induction of pRb2/p130 expression may overwhelm the ability of JCV TAg to alter pRb2/p130 phosphorylation. However, hyperphosphorylated pRb2/p130 was detectable in both the induced and uninduced states of HJC12 cells (Fig. 3, B) as well as in HJC⌬5 cells, which do not express any exogenous pRb2/p130 (data not shown). In both cases, the JCV TAg immunocomplex contained only hypophosphorylated pRb2/p130. This finding suggests that, if JCV TAg does indeed alter the phosphorylation state of pRb2/p130, it may do so by associating with hypophosphorylated pRb2/p130 and thereby blocking or delaying the phosphorylation of pRb2/p130. In addition, kinase activity of the cyclin-dependent kinases responsible for pRb2/p130 phosphorylation may be inhibited by the inactivation of pRb by JCV TAg. This situation would eliminate the pRb-mediated repression of the cdk-inhibitor p16 promoter, thereby leading to the induction of high levels of p16 that may inactivate some of the kinases involved in pRb2/p130 phosphorylation (36, 37) . Such a scenario may result in the rapid turnover of the protein if hypophosphorylated pRb2/p130 is inherently unstable. The possibility also remains that JCV TAg may accelerate the degradation of hyperphosphorylated pRb2/p130 through an indirect mechanism that does not require association of TAg with the hyperphosphorylated form of pRb2/p130. Both scenarios could indeed apply. A third explanation may be that, when JCV TAg associates with hyperphosphorylated pRb2/ p130, the kinetics of its reduction of the phosphorylation state of pRb2/p130 are too rapid to detect this complex.
The fact that induction of pRb2/p130 is able to overcome JCV TAg-mediated cellular transformation indicates that pRb2/ p130 is a critical target for the carcinogenic role of this oncoprotein. The importance of inactivation of pRb2/p130 function in deregulating growth control and giving cells a proliferative advantage is also supported by the observations in mice where targeted disruptions of multiple Rb-family proteins result in an enhanced or altered phenotype that is more severe than that of single-gene knock-out mice (38, 39) .
To our knowledge, we have shown for the first time that the induction of pRb2/p130 is growth suppressive to tumor formation in vivo. On average, the induction of pRb2/p130 retarded tumor growth, as measured by tumor weight, by 3.5-fold or 72% (95% CI ‫ס‬ 65%-78%). The hypothesis that RB2/p130 is a tumor suppressor gene is supported by this result, along with the mapping of the RB2/p130 locus to a region altered in several human neoplasms (23) , immunohistochemical data indicating an independent role for pRb2/p130 in the development and/or progression of human lung cancer (24, 25) and endometrial cancer (26) , and the identification of mutations in the RB2/p130 gene in human tumor cell lines (21, 27) and primary tumors (Cinti C, Claudio PP, Giordano A: unpublished data).
The JCV model serves as an excellent system to study the role of putative tumor suppressor genes and oncogenes in tumor formation and progression in vitro and in vivo (33) . The fact that the JCV TAg oncoprotein sequesters and inactivates several growth-regulatory and/or tumor suppressor genes such as p53 and the entire Rb family identified to date demonstrates that this system adheres to the theory of the multistep nature of cancer (1, (8) (9) (10) (11) . Our data support the notion that the correction of a single gene deficit can serve as a viable therapeutic alternative, even in the face of multiple genetic or epigenetic alterations. In an essentially Rb-family null background, the restoration of pRb2/p130 growth-regulatory function dramatically suppressed tumor formation in vivo of an otherwise highly proliferative and aggressive neoplasia. This finding, along with previous data demonstrating the growth-suppressive activity of pRb2/p130 in cell lines refractory to the effects of pRb/p105 and p107, suggests that RB2/p130 may be a candidate for the gene therapy of a variety of human cancers (28) . The antitumorigenic effects of pRb2/p130 expression may be even more dramatic in an immunocompetent host, where the immune system may be triggered and more capable of controlling or ridding the body of a neoplasia whose aggressive nature has been thwarted by enhanced pRb2/p130 expression. We are currently examining this theory, using the immunocompetent host of our inducible system, the Syrian golden hamster (Mesocricetus auratus). The direct effects of pRb2/p130 on JCV TAg-mediated cellular transformation itself may have profound implications on therapeutic alternatives in human diseases whose pathogenesis is thought to involve this polyomavirus. There have been reports of JCV in multiple malignant astrocytomas, primary cerebral malignant lymphoma, and oligoastrocytoma as well as in multiple gliomas in patients with PML (2, 13, 40, 41) . Many PML patients exhibit bizarre astrocytes with tumor-like glial changes (2) . It has been speculated that the short survival period of PML patients may not be sufficient to allow the full tumorigenic potential of JCV to become manifest, thus reflecting the relatively sparse number of patients with PML who develop gliomas (2) . The oncogenic potential of JCV may become more of a concern as treatments for PML improve. Since inhibition of viral replication enhances the tumorigenic potential of JCV TAg and thus results in tumor formation instead of PML and since 80% of the population is positive for JCV infection, the chance that this may occur by random mutations during propagation of the virus in the body, as has already been reported, could possibly account for a significant amount of morbidity and mortality in the human population (1, 13) . In addition, profound chromosomal damage in lymphocytes has been associated with JCV infection, and JCV has been implicated in the etiology of B-precursor acute lymphoblastic leukemia of childhood (42, 43) . Inactivation of pRb2/p130 function may play an intricate role in the pathogenesis of these diseases linked to JCV, and restoration of pRb2/p130 function may serve in the future as a viable therapeutic alternative to such disease and possibly to other human cancers.
